ACELYRIN INC. - COMMON STOCK

ACELYRIN, INC. Announces Leadership Transition

09 May 2024 08:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

29 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

28 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

20 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis

11 Mar 2024 08:02:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

11 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

15 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

20 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program

27 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights

07 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023

31 Oct 2023 16:30:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

11 Sep 2023 16:05:00 By Nasdaq GlobeNewswire